Clinical Trial: A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)

U.S., July 22 -- ClinicalTrials.gov registry received information related to the study (NCT07717840) titled 'A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)' on July 07.

Brief Summary: This Phase I/II study is to characterize the safety and immunogenicity of 2 dose levels of AZD6489, an investigational RSV recombinant prefusion F protein VLP vaccine.

Study Start Date: July 08

Study Type: INTERVENTIONAL

Condition: RSV Respiratory Syncytial Virus

Intervention: BIOLOGICAL: AZD6489

Participants will receive AZD6489 as a single intramuscular injection.

BIOLOGICAL: Licensed RSV vaccine #1

Participants will receive licensed RSV vaccine #1 as a single intramuscular injecti...